A U.S. District Court has given exclusivity rights to Shire for its ADHD drug Vyvanse. The decision comes in the wake of a lawsuit filed by Actavis Elizabeth which sought permission to begin selling a generic version of the drug.

"The FDA gave the ADHD drug Vyvanse (lisdexamfetamine disemsylate) five years of market exclusivity on account of its being a new chemical entity in 2007.

For that reason, it refused to file an approval application for a generic version of the drug submitted by Actavis Elizabeth. Actavis sued the FDA in February 2009 & to challenge the decision." [Source: Alaric DeArment, Drug Store News, March 4]

Shire's exclusivity will expire in February 2012. As a result, applications for generic versions can't be filed until then.

Like other popular ADHD medications (such as Ritalin and Adderall), Vyvanse is a stimulant that is used to control symptoms in children and adults.

Labels: medications, vyvanse

Posted By: Aspen/CRC